New version of Enzon cancer drug secures orphan status in EU

09/30/2008 | Boston Globe (tiered subscription model), The

European regulators granted orphan-drug status for Enzon Pharmaceuticals' Oncaspar-IV, a new version of its cancer drug for acute lymphoblastic leukemia. The designation prevents other drugmakers from selling copies of Oncaspar-IV for a decade should the product receive market clearance. Oncaspar-IV destroys cancer cells by depriving them of a key amino acid.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA